Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30464393 | 1.00 | MET (0.33) | METCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL25220796 | 0.88 | PKM (0.32) | METMCHR1MAPT | |
| SCHEMBL25275778 | 0.88 | PKM (0.32) | METMCHR1MAPT | |
| SCHEMBL25222644 | 0.87 | IL1B (0.33) | MET | |
| SCHEMBL30464446 | 0.87 | IL1B (0.33) | MET | |
| SCHEMBL25279111 | 0.87 | IL1B (0.33) | MET | |
| SCHEMBL25285585 | 0.86 | CHRM4 (0.34) | METCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL25218322 | 0.86 | CHRM4 (0.34) | METCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL25279915 | 0.86 | CHRM4 (0.34) | METCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL25263303 | 0.84 | SERPINE1 (0.36) | METCYP1A2CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | INCYTE CORPORATION | 2023-06-29 | — | — | US | disclosed |
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | INCYTE CORPORATION | 2023-06-29 | — | — | US | disclosed |
| WO-2023102184-A1 | BICYCLIC AMINE COMPOUNDS AS CDK12 INHIBITORS | INCYTE CORPORATION (US) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | CDK12, CDK1, CDK2 | MET 1571/4885CYP1A2 1325/4885CYP3A4 2861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.